SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors

被引:121
作者
Liu, LP
Stelmach, JE
Natarajan, SR
Chen, MH
Singh, SB
Schwartz, CD
Fitzgerald, CE
O'Keefe, SJ
Zaller, DM
Schmatz, DM
Doherty, JB
机构
[1] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Inflamat Res, Rahway, NJ 07065 USA
关键词
D O I
10.1016/j.bmcl.2003.08.059
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Development for a class of potent 3,4-dihydropyrido(3,2-d)pyrimidone inhibitors of p38a MAP kinase is described. Modification of N-1 aryl and C-6 arylsulfide in 3,4-dihydropyrido (3,2-d)pyrimidone analogues for the interaction with the hydrophobic pockets in p38 active site is also discussed. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3979 / 3982
页数:4
相关论文
共 19 条
[11]   Role of p38 mitogen-activated protein kinase in rhinovirus-induced cytokine production by bronchial epithelial cells [J].
Griego, SD ;
Weston, CB ;
Adams, JL ;
Tal-Singer, R ;
Dillon, SB .
JOURNAL OF IMMUNOLOGY, 2000, 165 (09) :5211-5220
[12]   Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket [J].
Gum, RJ ;
McLaughlin, MM ;
Kumar, S ;
Wang, ZL ;
Bower, MJ ;
Lee, JC ;
Adams, JL ;
Livi, GP ;
Goldsmith, EJ ;
Young, PR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (25) :15605-15610
[13]   A MAP KINASE TARGETED BY ENDOTOXIN AND HYPEROSMOLARITY IN MAMMALIAN-CELLS [J].
HAN, J ;
LEE, JD ;
BIBBS, L ;
ULEVITCH, RJ .
SCIENCE, 1994, 265 (5173) :808-811
[14]   A PROTEIN-KINASE INVOLVED IN THE REGULATION OF INFLAMMATORY CYTOKINE BIOSYNTHESIS [J].
LEE, JC ;
LAYDON, JT ;
MCDONNELL, PC ;
GALLAGHER, TF ;
KUMAR, S ;
GREEN, D ;
MCNULTY, D ;
BLUMENTHAL, MJ ;
HEYS, JR ;
LANDVATTER, SW ;
STRICKLER, JE ;
MCLAUGHLIN, MM ;
SIEMENS, IR ;
FISHER, SM ;
LIVI, GP ;
WHITE, JR ;
ADAMS, JL ;
YOUNG, PR .
NATURE, 1994, 372 (6508) :739-746
[15]   Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase [J].
Liverton, NJ ;
Butcher, JW ;
Claiborne, CF ;
Claremon, DA ;
Libby, BE ;
Nguyen, KT ;
Pitzenberger, SM ;
Selnick, HG ;
Smith, GR ;
Tebben, A ;
Vacca, JP ;
Varga, SL ;
Agarwal, L ;
Dancheck, K ;
Forsyth, AJ ;
Fletcher, DS ;
Frantz, B ;
Hanlon, WA ;
Harper, CF ;
Hofsess, SJ ;
Kostura, M ;
Lin, J ;
Luell, S ;
O'Neill, EA ;
Orevillo, CJ ;
Pang, M ;
Parsons, J ;
Rolando, A ;
Sahly, Y ;
Visco, DM ;
O'Keefe, SJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (12) :2180-2190
[16]   p38 MAP kinase inhibitors.: Part 1:: Design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold [J].
Natarajan, SR ;
Wisnoski, DD ;
Singh, SB ;
Stelmach, JE ;
O'Neill, EA ;
Schwartz, CD ;
Thompson, CM ;
Fitzgerald, CE ;
O'Keefe, SJ ;
Kumar, S ;
Hop, CECA ;
Zaller, DM ;
Schmatz, DM ;
Doherty, JB .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (02) :273-276
[17]   Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase [J].
Stelmach, JE ;
Liu, LP ;
Patela, SB ;
Pivnichny, JV ;
Scapin, G ;
Singh, S ;
Hop, CECA ;
Wang, Z ;
Strauss, JR ;
Cameron, PM ;
Nichols, EA ;
O'Keefe, SJ ;
O'Neill, EA ;
Schmatz, DM ;
Schwartz, CD ;
Thompson, CM ;
Zaller, DM ;
Doherty, JB .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (02) :277-280
[18]   Structural basis of inhibitor selectivity in MAP kinases [J].
Wang, ZL ;
Canagarajah, BJ ;
Boehm, JC ;
Kassisa, S ;
Cobb, MH ;
Young, PR ;
Abdel-Meguid, S ;
Adams, JL ;
Goldsmith, EJ .
STRUCTURE, 1998, 6 (09) :1117-1128
[19]   The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase [J].
Wilson, KP ;
McCaffrey, PG ;
Hsiao, K ;
Pazhanisamy, S ;
Galullo, V ;
Bemis, GW ;
Fitzgibbon, MJ ;
Garon, PR ;
Murcko, MA ;
Su, MSS .
CHEMISTRY & BIOLOGY, 1997, 4 (06) :423-431